Obermatt
See Similar Stocks →

Eurofins Scientific

PAR:ERF · FR0014000MR3
Life Sciences Tools & ServicesLarge

360

27
EV / EBIT85
Price / Owner Earnings18
Owner Earnings Yield53
Dividend Yield83
Price/Sales84
EV / Gross Profit53
Price/Book44
Return on Capital65
Cash Return on Capital45
Return on Equity62
EBIT Margin51
Gross Profitability31
Cash Conversion82
Accruals38
Owner Earnings Margin43
Sales growth46
Profit Growth96
Long-Term EPS Growth55
Owner Earnings Growth14
Reinvestment45
Price momentum65
Debt load44
Refinancing65
Debt Payback13
Liquidity67
Analyst ratings5
Opinion Changes44
Price Target Upside35
Market mood65
Value Creation12/20creating some value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Eurofins Scientific clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Profile

CountryLuxembourg
IndustryLife Sciences Tools & Services
SizeLarge
TypePublic Company
ExchangeENXTPA
Employees9,915
Websiteeurofins.com
ISINFR0014000MR3
Last UpdateApr 2, 2026
Indices
CAC 40 (France)CAC All (France)SBF 120 (France)Sound Pay Practices (Europe)
Themes
Health DiagnosticsEnvironment, Health and Safety (EH&S)Environmental ConsultingGeneticsService Industry

Description

Eurofins Scientific SE, a life sciences company, provides analytical testing services to clients from various industries, including the pharmaceutical, food, and environmental sectors internationally. The company specializes in delivering analytical…

Analysis

Middle-of-the-road

Eurofins Scientific SE is a middle-of-the-road business: neither the economics nor the price stand out from the peer group.

The price is expensive. You pay 53.6× its owner earnings: the cash an owner could take out each year, which is in the historically expensive zone. At today's price, the market is assuming roughly 19% yearly growth; analysts expect 11%. The gap between price and consensus is worth watching: demanding expectations.

The trajectory is moderate and the balance sheet is stretched. The company scores 12/20 on our value-creation score: creating some value. Analyst sentiment is cautious.

What to watch: A large part of the company's book value is the price paid for past acquisitions. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
83
2023202420252026

All-time high

83

Jun 2026

All-time low

13

Jan 2023

Average rank

59

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
84
69
59
56
Price/Earnings
38
61
38
43
Price/Book
44
72
61
56
Dividend Yield
83
37
55
53
Value (overall)
86
72
75
71

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Eurofins Scientific with its peers
AddLife
STO:ALIF B
83
CountrySweden
IndustryLife Sciences Tools & Services
SizeMedium
Full Stock Analysis →
Sartorius
GER:SRT
11
CountryGermany
IndustryLife Sciences Tools & Services
SizeLarge
Full Stock Analysis →
Sartorius Stedim
PAR:DIM
15
CountryGermany
IndustryLife Sciences Tools & Services
SizeLarge
Full Stock Analysis →
Tecan Group
SWX:TECN
25
CountrySwitzerland
IndustryLife Sciences Tools & Services
SizeSmall
Full Stock Analysis →
Bureau Veritas
PAR:BVI
77
CountryFrance
IndustryProfessional Services
SizeX-Large
Full Stock Analysis →
MDxHealth
NAQ:MDXH
43
CountryBelgium
IndustryBiotechnology
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →